Washington

MYLAN faces an increasing backlash over its handling of the EpiPen pricing controversy, as a top proxy adviser urged shareholders to oust the drugmaker's board.

Institutional Shareholder Services (ISS) said that the company's directors had failed to stop "significant destruction in shareholder value". ISS took issue with the company's governance on a broad scale and faulted the board for making "egregious" decisions on pay.